Source: Annual Congress 2011 - Treatment strategies, systemic manifestations and biomarkers in airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Strohner, A. Staatz, A. Schaefer, G. Becher, D. Sarrach, J. Reich, T. Haeupl, J. O. Steiss (Berlin, Bernau, Giessen, Germany). Monitoring of efficacy of therapy with monoclonal antibodies – Omalizumab – Using the Recovery-ELISA. Eur Respir J 2011; 38: Suppl. 55, 4054

Member's Comments

No comment yet.

Related content which might interest you: Adenovirus IgG avidity – A marker of outcome in COPD-exacerbations Source: Annual Congress 2012 - COPD treatment and varia Year: 2012 Treatment of sarcoidosis – pentoxifylline Source: Annual Congress 2009 - Pleural and parenchymal diseases Year: 2009 T spot TB reactivity – ²to treat or not to treat² Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 The results of drug resistance survey of MDR-strains on second line drugs obtains in national reference laboratory – " M.Nasta " Institute – Bucharest Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 The in-vitro pharmacology of PF-4522971 – A novel inhaled Muscarinic M3 Antagonist Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Cetuximab maintenance therapy – How long should we proceed? A case report Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011 Patients‘ knowledge about inhalation therapy in pulmology – One year after intervention Source: Annual Congress 2011 - Medical education Year: 2011 Cryptogenic organising pneumonia – clarithromycin treatment – factors influencing treatment results and relapses Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Airway resistances: Raw, sRaw, sReff – Which is the best determinant of airway function? Source: Annual Congress 2010 - Lung function from infancy to adulthood Year: 2010 The in-vitro pharmacology of PF-3429281 – A novel inhaled dual antimuscarinic/β2 adrenoceptor agonist Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010 Asthma medication and antibiotics – Cause or effect? Source: Annual Congress 2010 - Paediatric respiratory epidemiology: early origins of childhood asthma Year: 2010 Triple 0 – A new respiratory syndrome? Source: Annual Congress 2012 - Advanced experience with long-term noninvasive ventilation and late-breaking abstracts Year: 2012 CREWS – A preliminary evaluation Source: Annual Congress 2010 - Palliative care, oxygen and community care for chronic lung disease Year: 2010 Asthma in elderly – What is the difference? Source: Annual Congress 2012 - Distinguishing phenotypes and dealing with comorbidities in primary care Year: 2012 Oral glucocorticoid treatment of severe asthma – Current practice in the US Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Adrenomedullin – a protective factor in asthma? Source: Annual Congress 2009 - Animal models of airways inflammation Year: 2009 Cof a 1 – Identification of the first coffee allergen Source: Annual Congress 2012 - Occupational asthma Year: 2012 Long term inhalatory therapy in asthma – Achieving control of the disease Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management Year: 2012 EGFR – a useful biomarker? Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009 Plasma levels of alpha crystalline antibodies in NSCLC patients – Diagnostic significance Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010